AbbVie is undervalued with strong EPS growth, rising immunology revenue, and a 3.43% yield. Check out ABBV's robust pipeline ...

Altria’s shrinking core business, strained cash flow, and failed smoke-free pivot threaten its dividend and valuation outlook ...

Non-GAAP diluted EPS* Represents EPS (net income per diluted common share attributable to L3Harris Technologies, Inc. common shareholders) adjusted for items reconciled in Table 7. Pension ...

Currency Exchange International, Corp. (the “Group” or “CXI”) (TSX: CXI; OTCQX: CURN), today reported net income of $1.98 million for the second quarter ...

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.

Canaccord Genuity Group Inc. reported its fiscal Q4 2025 earnings, revealing a miss in earnings per share (EPS) forecasts with an actual ... a strong financial position with a healthy current ratio of ...

The company anticipates a challenging second quarter because of higher tariffs and other costs. EPS is expected to decline by 45%-50% year over year. Because Dollar Tree will bear the full year of the ...

Verint projects Q2 2025 revenue of $200 million and a diluted EPS of $0.26, reflecting a cautious yet optimistic outlook. The company anticipates full-year revenue of approximately $960 million ...

2025 Full-Year Forecast PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on April 23, 2025, of $7.01 to $7.14. Excluding a total 2025 adjustment of $0.35 per share and a ...

In stark contrast, normalized EBITDA plunged 34.7% to $200.8 million, while normalized net income tumbled 71% to $34.6 million, reducing normalized diluted EPS to just $0.47 from $1.58 a year earlier.